Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant

Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant

Abstract Background Endocrine therapies targeting estrogen signaling have significantly improved breast cancer (BC) patient survival, although 40% of ERα-positive BCs do not respond to those therapies. Aside from genomic signaling, estrogen triggers non-genomic pathways by forming a complex containi...

Full description

Bibliographic Details
Main Authors: Julien Jacquemetton, Loay Kassem, Coralie Poulard, Ahmed Dahmani, Ludmilla De Plater, Elodie Montaudon, Laura Sourd, Ludivine Morisset, Rania El Botty, Sophie Chateau-Joubert, Sophie Vacher, Ivan Bièche, Isabelle Treilleux, Olivier Trédan, Elisabetta Marangoni, Muriel Le Romancer
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Breast Cancer Research
Subjects:
Breast cancer
Estrogen signaling
Resistance
PI3K
PDX
Biomarker
Online Access:https://doi.org/10.1186/s13058-021-01433-8

Internet

https://doi.org/10.1186/s13058-021-01433-8

Similar Items